Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer

• Published in: Japanese journal of radiology Vol. 34; no. 3; pp. 220 - 228
• Main Authors: Kitajima, Kazuhiro, Fukushima, Kazuhito, Miyoshi, Yasuo, Katsuura, Takayuki, Igarashi, Yoko, Kawanaka, Yusuke, Mouri, Miya, Maruyama, Kaoru, Yamano, Toshiko, Doi, Hiroshi, Yamakado, Koichiro, Hirota, Seiichi, Hirota, Shozo
• Format: Journal Article
• Language: English
• Published: Japan 01.03.2016
• Subjects: Adult; Aged; Aged, 80 and over; Axilla; Breast Neoplasms - diagnostic imaging; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes - diagnostic imaging; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Breast cancer; Axillary lymph node; Prognosis; 18F-FDG; PET/CT
• ISSN: 1867-108X
• DOI: 10.1007/s11604-015-0515-1

To investigate the diagnostic and prognostic value of (18)F-FDG-PET/CT for axillary lymph node (LN) staging in breast cancer patients, employing histologic evaluation as the reference. Among 196 patients with biopsy-proven breast cancer who had undergone (18)F-FDG-PET/CT before mastectomy or breast-conserving surgery with sentinel LN biopsy and/or axillary LN dissection, 200 axillae were retrospectively analyzed by visual assessment and quantitatively using SUVmax. LN SUVmax as well as other clinicopathological features were assessed for their prognostic value using the log-rank test and Cox method. Metastasis was diagnosed histopathologically in 56 (28 %) axillae. The sensitivity, specificity, and accuracy of visual PET/CT for diagnosing node metastasis were 55.4, 95.8, and 84.5 %, respectively. When the optimal discriminative SUVmax cutoff was 1.5, these figures were 51.8, 97.2, and 84.5 %, respectively. Fourteen of 55 patients (25.5 %) with LN metastases suffered a recurrence during follow-up (median 39 months). Patients with a high nodal SUVmax (≥1.7) had a significantly lower progression-free survival rate than those with a low SUVmax (p = 0.0499). Axillary nodal and primary tumor SUVmax as well as estrogen receptor status were significantly associated with recurrence. Axillary nodal SUVmax may be a prognostic indicator of disease recurrence in patients with axillary LN metastases.